Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
Calleja, Jose Luis (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Rivera-Esteban, Jesús (Universitat Autònoma de Barcelona)
Aller, Rocio (Universidad de Valladolid. BioCritic)
Hernández-Conde, Marta (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Abad, Javier (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Pericàs, Juan M. (Hospital Universitari Vall d'Hebron)
Benito, Hugo G. (Instituto de Estudios de Ciencias de la Salud de Castilla y León)
Serra, Miguel A. (Universitat de València)
Escudero, Amparo (Universitat de València)
Ampuero, Javier (Universidad de Sevilla)
Lucena, Ana (Universidad de Sevilla)
Sánchez, Yolanda (Universidad de Sevilla)
Arias-Loste, Maria T. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Iruzubieta, Paula (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Romero-Gómez, Manuel (Universidad de Sevilla)
Augustin Recio, Salvador (Hospital Universitari Vall d'Hebron)
Crespo García, Javier (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))

Fecha:	2022
Resumen:	Background & Aims: Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non-alcoholic steatohepatitis (NASH) is largely unknown in the general population. This study aimed to provide an updated estimation of the prevalence of NASH fibrosis in Spain. Methods: This was an observational, retrospective, cross-sectional, population-based study with merged data from two Spanish datasets: a large (N = 12 246) population-based cohort (ETHON), including transient elastography (TE) data, and a contemporary multi-centric biopsy-proven NASH cohort with paired TE data from tertiary centres (N = 501). Prevalence for each NASH fibrosis stage was estimated by crossing TE data from ETHON dataset with histology data from the biopsy-proven cohort. Results: From the patients with valid TE in ETHON dataset (N = 11 440), 5. 61% (95% confidence interval [95% CI]: 2. 53-11. 97) had a liver stiffness measurement (LSM) ≥ 8 kPa. The proportion attributable to NAFLD (using clinical variables and Controlled Attenuation Parameter) was 57. 3% and thus, the estimated prevalence of population with LSM ≥ 8 kPa because of NAFLD was 3. 21% (95% CI 1. 13-8. 75). In the biopsy-proven NASH cohort, 389 patients had LSM ≥ 8 kPa. Among these, 37% did not have significant fibrosis (F2-4). The estimated prevalence of NASH F2-3 and cirrhosis in Spain's adult population were 1. 33% (95% CI 0. 29-5. 98) and 0. 70% (95% CI 0. 10-4. 95) respectively. Conclusions: These estimations provide an accurate picture of the current prevalence of NASH-related fibrosis in Spain and can serve as reference point for dimensioning the therapeutic efforts that will be required as NASH therapies become available.
Ayudas:	Instituto de Salud Carlos III PI18/01304
Nota:	Altres ajuts: acords transformatius de la UAB
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Hepatic fibrosis ; Liver biopsy ; Non-alcoholic steatohepatitis ; Transient elastography
Publicado en:	Liver International, 2022 , ISSN 1478-3231

DOI: 10.1111/liv.15323
PMID: 35643936

10 p, 584.0 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados